Objective: Non-psychological parameters may predict pump success.
Methods: Review was performed on 35 implants for gender, age, pretrial/trial dose, baseline visual analog scale (VAS), and pain location. One-year outcomes were % change VAS/intrathecal dose and medication change. Spearman coefficients correlated pretrial/trial dose, age, baseline VAS, and % change in VAS/intrathecal dose. Wilcoxon Rank-Sum tests correlated gender/pain location and % change in VAS/intrathecal dose. Pretrial/trial dose, baseline VAS, and medication change was tested using Wilcoxon Rank-Sums. Chi-square was used to correlate medication change with gender/pain location. A two-sample t-test compared age and medication change.
Results: Positive correlation between % change VAS and trial dose was noted. Greater age correlated with lower VAS and % dose change. Marginally significant difference in % dose change by pain location was present with higher doses for leg pain.
Conclusion: Trial dose, age, and partially pain location are good predictors of pain relief.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1525-1403.2011.00333.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
Neurology
February 2025
Department of Neurology and Center of Clinical Neuroscience, First Medical Faculty, General University Hospital and Charles University, Prague, Czech Republic.
Background And Objectives: Patients with multiple sclerosis (MS) may demonstrate better disease control when treatment is initiated on high-efficacy disease-modifying therapies (DMTs) from onset. This subgroup analysis assessed the long-term efficacy and safety profile of the high-efficacy DMT ocrelizumab (OCR) as first-line therapy for early-stage relapsing MS (RMS).
Methods: Post hoc exploratory analyses of efficacy and safety were performed in a subgroup of treatment-naive patients with RMS who received ≥1 dose of OCR in the multicenter OPERA I/II (NCT01247324/NCT01412333) studies.
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
J Clin Oncol
January 2025
Center for Cell Engineering, Sloan Kettering Institute, New York, NY.
Purpose: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that 1XX CARs generated potent effector function without undermining T-cell persistence. We hypothesized that 1XX CAR T cells may be effective at low doses and elicit minimal toxicities.
View Article and Find Full Text PDFA Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix Vaccine When Given to Healthy Infants at 3 and 12 Months of Age.
Infect Dis Ther
January 2025
Vaccine Research and Development, Pfizer R&D UK Ltd, Marlow, UK.
Introduction: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) in infants were evaluated.
Methods: In this phase 3b, open-label, single-arm study, healthy 3-month-old infants received a single Nimenrix dose followed by a booster at age 12 months (1 + 1 series).
Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.
Invest New Drugs
January 2025
Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Background: Immune checkpoint inhibitors (ICIs) combined with anti-vascular endothelial growth factor (VEGF) have been the standard first-line treatment of hepatocellular carcinoma (HCC). However, the efficacy of this combination in post-line treatment is still unknown. This study aimed to evaluate the efficacy and safety of the combination of anti-PD-L1 envafolimab and novel humanized anti-VEGF suvemcitug as second-line treatment for patients with HCC.
View Article and Find Full Text PDFAn early evaluation of robot-assisted and conventional techniques for posterior approach atlantoaxial displacement instrumentation - a systematic review and meta-analysis.
Neurosurg Rev
January 2025
Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, 41-808, Poland.
Atlantoaxial dislocation (AAD) is a serious condition in which the first two cervical vertebrae lose their anatomical position and stability. This may lead to neurological complications, including death. The treatment of AAD remains controversial, and posterior instrumentation with pedicle screw placement is one of the commonly used methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!